Morgan Stanley Maintains Overweight on Definitive Healthcare, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Craig Hettenbach has maintained an Overweight rating on Definitive Healthcare (NASDAQ:DH), but lowered the price target from $17 to $15.
August 15, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Definitive Healthcare, but lowered the price target from $17 to $15.
The news is directly related to Definitive Healthcare. While the Overweight rating suggests that Morgan Stanley expects the stock to outperform, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100